Stereotactic ablative radiotherapy and stereotactic body radiotherapy to the primary tumour or metastases combined with EGFR-TKIs or first-line chemotherapy (for patients without EGFR mutations) significantly prolonged PFS and OS in patients with oligometastatic NSCLC (16, 24–28). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.